Jerzy Szewczyk

Dr. George Szewczyk, Co-Founder of BioKier, has been the CEO and CSO since its inception in November 2008. He is the inventor of the BioKier Intellectual Property, which came from his novel approach to treatment of type 2 diabetes. Dr. Szewczyk created the clinical strategy for the BioKier drug and is currently overseeing the Company’s ongoing clinical studies. Additionally he is expanding the Company’s patent portfolio.

Dr. Szewczyk has more than 15 years working for GlaxoSmithKline and legacy organizations where he led cross-disciplinary teams in drug discovery efforts. Dr. Szewczyk has considerable experience in pharmaceutical research and development in the area of metabolic diseases, including obesity and diabetes. He has experience in collaboration with scientists in other disciplines, including pharmacokinetics, biology, biochemistry, clinical and regulatory, and has an in-depth understanding of drug development.

Dr. Szewczyk was educated at Technical University of Gdansk, Poland where he earned his Ms.S. and a doctorate in Medicinal Chemistry and Drug Synthesis. He worked at Technical University of Gdansk as adjunct professor and then spent three years as Duke University as research scientist.

Subsequently, Dr. Szewczyk worked for 6 years at Research Triangle Institute where, among other accomplishments, he developed a novel synthesis of galanthamine (Reminyl/Razadyne). From 1992 to 2008 he worked at Glaxo, GlaxoWellcome and GSK.